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Abstract
Introduction: Follicular Lesion of Undetermined Significance (FLUS) belongs to the most controversial category of the Bethesda System. 
The aim of the study was to specify the risk of malignancy in patients with FLUS diagnosis in the material from the Institute of Oncology 
in Gliwice. This is the first Polish study specifying the risk of malignant neoplasm presence when Fine-Needle Aspiration Biopsy (FNAB) 
results in a report of diagnostic category III (DC III). 
Material and methods: Three hundred and ninety-five primary DC III diagnoses from FNABs of the thyroid gland performed from 
2010 to 2015 were analysed. Correspondence of DC III with diagnoses from repeated FNABs and histopathology reports was evaluated.
Results: From 395 DC III patients, 27 were treated surgically for clinical indications, receiving six diagnoses of cancer. Repeat FNAB was 
performed in 180 cases, and primary diagnosis was confirmed in 41 cases. In the second FNAB there was one diagnosis of “Papillary 
Thyroid Carcinoma” and one “Suspicious for Papillary Thyroid Carcinoma”. From eight patients treated surgically in these series prior 
cytological cancer diagnosis was confirmed in two cases. Forty-six patients were subjected to third and subsequent FNABs; in one case 
the diagnosis was “Suspicious for Malignancy”. In the analysed material the risk of cancer in patients with FLUS is 2.78%. Taking into 
account all 56 subsequent FNABs in which the primary diagnosis was confirmed, the risk decreases to 2.43%.
Conclusions: The diagnosis of FLUS in the absence of clinical indications is not a basis for surgical treatment. 
(Endokrynol Pol 2016; 67 (1): 12–16)
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Streszczenie
Wstęp: Zmiana pęcherzykowa bliżej nieokreślona (grupa III) należy do najbardziej kontrowersyjnej kategorii systemu Bethesda. Brak jest 
polskich opracowań określających stopień ryzyka wystąpienia nowotworu złośliwego po rozpoznaniu zmiany z grupy III.
Celem pracy było określenie ryzyka złośliwości po rozpoznaniu zmiany pęcherzykowej bliżej nieokreślonej w materiale Centrum On-
kologii w Gliwicach.
Materiał i metody: Analizie poddano 395 rozpoznań z grupy III BAC tarczycy wykonanych w latach 2010–2015. Oceniono zgodność 
pierwotnego rozpoznania grupy III z rozpoznaniami z kolejnych BAC i wynikami badań histopatologicznych.
Wyniki: Na 395 rozpoznań grupy III zoperowano ze wskazań klinicznych 27 pacjentów i rozpoznano 6 raków. Ponowną BAC wykonano 
w 180 przypadkach i pierwotne rozpoznanie potwierdzono w 41 przypadkach. Po drugiej BAC 2-krotnie rozpoznano raka brodawkowa-
tego lub jego podejrzenie. U 8 operowanych w tej serii potwierdzono wcześniejsze cytologiczne rozpoznanie raka u 2. Trzecią i kolejne 
BAC wykonano u 46 pacjentów i w jednym przypadku podejrzewano raka.
Ryzyko raka w zmianie pęcherzykowej bliżej nieokreślonej w analizowanym materiale wynosi 2,78%. Uwzględniając wszystkie powtórnie 
wykonane 56 BAC, w których potwierdzono pierwotne rozpoznanie grupy III, ryzyko maleje do 2,43%.
Wnioski: Rozpoznanie zmiany pęcherzykowej bliżej nieokreślonej przy braku wskazań klinicznych nie jest podstawą do wszczęcia 
postępowania chirurgicznego. (Endokrynol Pol 2016; 67 (1): 12–16)
Słowa kluczowe: guzek tarczycy; rak tarczycy; biopsja aspiracyjna cienkoigłowa
Introduction
The progress of ultrasonographic techniques and meth-
ods of interpretation of Fine-Needle Aspiration (FNA) 
cytology caused an increase in the value of this test in 
routine diagnostics of thyroid nodules. The implemen-
tation of the Bethesda System for Reporting Thyroid 
Cytopathology (BSRTC) as a standard in FNA evalua-
tion improved clinical management (Table I). FNA is an 
accessible, cost-effective, quick and safe method, and 
the diagnostic success depends on the performance and 
right interpretation. The categorisation of cytological 
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The aim of the study was to specify the risk of ma-
lignancy in patients with FLUS diagnosis in the material 
from the Institute of Oncology in Gliwice.
Material and methods
16,656 reports of thyroid FNA were generated in 
the Department of Tumour Pathology of Maria Sklo-
dowska-Curie Memorial Cancer Centre and Institute 
of Oncology, Gliwice Branch from January 2010 to 
April 2015. All FNAs were performed in two-person 
teams including a pathologist and a radiologist, under 
ultrasound guidance. The material was obtained by 
25-gauge needles, and direct smears were alcohol-fixed 
and stained with haematoxylin-eosin. All of the evalua-
tions and reports were provided by the pathology spe-
cialists. Each test contained a description of the site of 
the biopsy with the size of the nodule and ultrasound 
photography. The questionable cases were consulted 
by another pathologist. Our analysis concerns 395 
diagnoses of DC III that were rendered from January 
2010 to April 2015.
Results
We analysed 16,656 FNA, from which DC III was re-
ported in 395 cases (Fig. 1 and 2). After initial diagnosis 
of DC III, 180 (45.5%) patients underwent repeat FNA, 
27 (6.8%) patients were operated on, and 188 (47.6%) 
did not undergo additional sampling or surgery at 
the study institution and were moved to surveillance. 
Twenty-seven thyroidectomies after initial DC III 
yielded six cancers and 21 benign changes. In 180 cases 
repeat FNA was performed, from which the diagnosis 
of DC I or DC II was established 109 times (60.5%); 
41 (22.7%) patients again obtained DC III (36 were put 
under observation after that, five had another [third] 
FNA). The remaining 30 patients had DC IV, DC V, or 
diagnoses in six groups allowed improvement in the 
communication and specifying of the right clinical 
management [1–6].
Diagnostic category III (DC III): atypia of unde-
termined significance/follicular lesion of undeter-
mined significance (AUS/FLUS) has been the most 
controversial category of the BSRTC. It is a category 
of exclusion, which should be used exceptionally — 
in up to 7% of cytological reports [7]. The images 
from this group usually do not fulfill the criteria of 
other groups and require correlation with clinical 
presentation along with repeat FNA. The expected 
risk of malignancy in this class ranges between 
5 and 15% [2, 7]. The creation of this category reduces 
the malignancy risk and the number of unnecessary 
surgical interventions in favour of repeat FNA and 
correlations of cytological, clinical, and ultrasono-
graphic presentation [7, 8].
BSRTC was introduced for the evaluation of cytolog-
ical smears from thyroid FNA in 2010 in Poland, hence 
the creation of DC III improved the dialogue between 
the surgeon, the endocrinologist, and the pathologist, 
and what is most important, precisely defined the clini-
cal management.
The six-tier scale established by the Polish Work-
group is accurately characterised and contains some 
minor alterations to the one proposed by the NCIS. In 
“our” scale there is an exact description of DC III: “The 
aspirate should be rather cell-rich, with marked domi-
nation of small structures (groups, nests, rosettes) on 
the colloid background. Such elements as macrophages, 
lymphocytes, or plasma cells are admissible. This cat-
egory is not an indication for surgical treatment and 
the biopsy should be repeated.” The Polish Workgroup 
excluded the criterion of cellular atypia from our defi-
nition [9]. We believe this minor modification carries 
important clinical implications, which are reflected in 
our analysis.
Table I. The Bethesda System for Reporting Thyroid Cytopathology: Implied risk of malignancy and recommended clinical 
management [2]
Tabela I. Klasyfikacja cytopatologii tarczycy według systemu Bethesda [2]
Diagnostic Category Risk of Malignancy (%) Usual Management
Nondiagnostic or Unsatisfactory 1–4 Repeat FNA with ultrasound guidance
Benign 0–3 Clinical follow-up
Atypia of Undetermined Significance or Follicular Lesion of Undetermined 
Significance
5–15 Repeat FNA
Follicular Neoplasm or Suspicious for a Follicular Neoplasm 15–30 Surgical lobectomy
Suspicious for Malignancy 60–75 Near-total thyroidectomy or surgical lobectomy
Malignant 97–99 Near-total thyroidectomy
The Bethesda System for Reporting Thyroid Cytopathology: Implied Risk of Malignancy and Recommended Clinical Management
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DC VI, from which eight were treated surgically (two 
cancers, six benign changes), and 14 were subjected 
to observation. Altogether, third FNA was performed 
in 46 cases, giving DC III (10×), DC IV, V, VI (3×), and 
DC I or II (33×). Four and more FNAs were performed 
in 10 (in 395) patients (4× DC III, 1× DC V, 5× DC I or 
II), and all these patients were being further observed. 
In summary, from 395 FNAs with DC III, 34 patients 
underwent surgery (27 after first diagnosis of DC III 
and eight after second biopsy diagnosis of DC IV, V, 
or VI) obtaining the histopathological reports of six 
cancers after first biopsy with DC III diagnosis, and 
two cancers after second biopsy with the diagnosis of 
category of higher acuity than DC III.
Discussion
The Bethesda System allows qualification of FNA diag-
noses to six categories, which eases subsequent clinical 
management. It supports providing a brief diagnosis 
(as the description of the cytological image might be 
too expanded and illegible), hence defining the level 
of risk assigned to each of the six categories. The sug-
gested frequency of DC III reporting is about 7%, and 
the expected risk of malignancy assigned for DC III is 
in the range of 5–15%. The most important feature of 
DC III is the definition of patients’ management. The 
Bethesda System in principle recommends repeat FNA 
if there are no other clinical implications.
DC I, DCII
n = 15 509
Total FNAs
n = 16 656
DC III
n = 395
DC IV
n = 352
DC V
n = 290
DC VI
n = 110
Observation
n = 188
Repeat 
(2nd) FNA
n = 180
Restriction
n = 27
DC I, DC II
n = 109
DC III
n = 41
Malignant
n = 6
Beginin
n = 21Observation
n = 14
Restriction
n = 8
Observation
n = 36
Observation
n = 76
Malignant
n = 2
Beginin
n = 6
Repeat 
(3rd) FNA
n = 33
Repeat 
(3rd) FNA
n = 5
Repeat 
(3nd) FNA
n = 8
DC IV, DC V, DC VI
n = 30
Figure 1. CONSORT diagram of the study group
Rycina 1. Diagram CONSORT analizowanej grupy pacjentów
Figure 2. Representative examples of Bethesda Diagnostic Category III FNAs. Staining: haematoxylin-eosin
Rycina 2. Reprezentatywne przykłady rozmazów z biopsji aspiracyjnej cienkoigłowej tarczycy z kategorii III klasyfikacji Bethesda. 
Barwienie: hematoksylina-eozyna
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In 16,656 examined FNAs we obtained 395 FLUS, 
which comprises 2.3%. The percentage of DC III con-
siderably varies between the studies. Kholova et al. 
presented a meta-analysis of 20 retrospective and six 
prospective studies. The percentage of DC III is vari-
able, ranging from 0.8% to 27%. It was observed that 
the most numerous groups that were analysed (7–8000 
FNAs) obtained the percentage of 2–3% [10]. Harvey et 
al. in their analysis achieved a ratio of 2.3% (79/3432), 
similar to ours [8]. Broome et al. stated in their study 
that the number of DC III diagnoses in their institu-
tion comprised 10%; moreover, they demonstrated 
how this percentage altered in particular years: 7.4%, 
11.8%, 11.5%, 8.3% in 2009–2012, respectively [11]. In the 
literature there are some studies available which show 
a definitely higher percentage of DC III. The research of 
Jo et al. revealed 15.5% AUS (61/393) [12]. Similar results 
were displayed in a prospective study based on a small 
study group (11 AUS/225 FNA), in which the observa-
tion was continued only for two years [13].
FNA evaluation requires long experience and wide 
cytological knowledge. The possibility of consultation 
between the competent pathologists regarding aspirates 
examination is essential. Most of the shown analyses 
concern the work of cytopathologists or pathologists 
that deal with cytological diagnostics of the thyroid 
on a daily basis [1, 4, 10, 11]. The authors of one of the 
large studies base the initial diagnostics on the work of 
screeners. However, the published data do not differ 
from other analyses [8].
The Bethesda System imposes a certain scheme 
of procedure and sets the clinical indications: DC III 
diagnosis is to be followed by repeat FNA.
In our study, after obtaining DC III in 395 patients 
180 (45.5%) had repeat FNA (215 patients were either 
operated on or put under observation). In the study 
by Srbova et al. we encountered similar numbers: 57% 
of repeat FNA [14]. One hundred and eighty-nine pa-
tients did not undergo invasive procedures, which may 
mean that they resigned from repeat FNAs and were 
subjected to observation only, or were moved to other 
medical centres. The remaining 180 patients followed 
the recommendations strictly.
Other researchers indicated that repeat FNA after 
initial DC III was performed in 6.8% [7] and 33% [11] 
of cases, and a meta-analysis of 10 studies demon-
strated an average performance of repeat FNA rang-
ing from 9.39% to 20.5% [10]. In the study repeat FNA 
was performed 26 times, which comprises 46.4% [15]. 
These data are considerably divergent, but that prob-
ably depends on different socio-economic conditions. 
Broome et al. mentioned that the factor that directly 
influenced the number of repeat FNAs, and hence the 
number of surgical interventions was the patient’s 
decision [11]. Patients that do not accept the “wait and 
watch” approach can choose thyroidectomy. In our 
medical centre, following the National Health Fund 
recommendations and taking into consideration that 
the queues for oncological treatment are long, the 
waiting time for an operation for patients with double 
DC III diagnosis is at least six months. Taking this into 
account, the recommendation of repeat FNA after first 
diagnosis of DC III is usually followed. Our patients 
do not have the possibility to choose either “watchful 
waiting” strategy and a repeat FNA after six months or 
a more radical procedure, which is less stressful for them.
In our analysis, after first DC III diagnosis 27 (6.8%) 
patients were subjected to surgical treatment because of 
urgent clinical indications (enlarged and/or suspicious 
lymph nodes, active neoplastic disease or family history 
of cancer). In the world, many resections are performed 
after initial DC III diagnosis. The authors of many arti-
cles explained that the reason is the concern about the 
patients and bending to their will when they do not 
want to wait, be observed, and subjected to repeat FNA 
after the initial diagnosis of an unequivocal change. Ho 
et al. in the analysis of 541 DC III diagnoses reported 
surgical removal in 350/541 (64.7%) cases [7]. Harvey et 
al. showed 25% (18/72) of excisions [8]. 
Even if for the sake of patient the number of surgical 
procedures is high, the percentage of operations before 
and after the implementation of the Bethesda System 
has diminished significantly. Joy et al. compared two 
groups of patients: one categorised before the creation 
of Bethesda System (BS) and another, similar in num-
ber, in which the diagnoses were compatible with the 
recommendations of the BS. The researchers noticed 
that the implementation of DC III caused a reduction 
in the number of thyroidectomies [15].
The limitation of unnecessary surgical interventions 
is at the opposite pole of the problem of assessing the 
risk of malignancy after DC III diagnosis. In our institu-
tion operations after initial DC III diagnosis concerned 
27/395 (6.8%) patients. They were performed because 
of urgent clinical indications when the cytological 
diagnosis (DC III) did not correspond with the suspi-
cious clinical picture. There were 6/27 (22%) malignant 
changes operated after first DC III diagnosis; altogether 
cancers comprised 6/395 (1.5%).
Altogether we reported 8/395 (2.02%) cancers after 
two FNAs. Subsequent FNAs did not give the diagnoses 
of cancer (46 patients had three FNAs, 10 had four or 
more FNAs).
Ho et al. in the analysis of 541 DC III cases described 
350/541 (64.7%) operations. More than half of their 
patients were operated on “offhand”. They received 
135 diagnoses of malignancies (38.6%), and after 
subsequent FNA with DC III 12 patients had surgical 
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treatment, obtaining four diagnoses of malignancies 
[7]. Meta-analysis based on 26 studies showed 34% 
risk of malignancy [10]. Wu et al. reported 7% risk of 
malignancy [5].
It appears that risk of malignancy shown as this, 
regardless of so much data, is unclear for DC III, be-
cause the divergence of the results presented by the 
researchers is quite remarkable and depends on many 
factors, such as the size of the group, strict following 
of the recommendations of the Bethesda System, and 
the clinical consequences.
We have to admit that we operate on far fewer 
patients, but not only due to the long queues for the 
surgical treatment. It appears that DC III — FLUS 
adapted by us by elimination of the cytological speci-
mens containing atypical cells became more uniform 
and more effective in reducing the risk of malignancy 
for this category. The recommended risk of malignancy 
for a nodule with this diagnosis in Poland was not 
supposed to exceed 5% in the assumptions made by 
the Polish Workgroup [9]. After first FNA with DC III 
diagnosis we operated on 27 patients receiving reports 
of six cancers, after second BAC we obtained two di-
agnoses of malignancies. In eight cases operated on in 
this series previous cytological diagnosis of cancer was 
histopathologically confirmed in two patients. Third 
and subsequent FNA was performed in 46 patients, 
and in one case there was a suspicion of malignancy, 
but there were no operations performed.
In our material the risk of malignancy in Follicular 
Lesion of Undetermined Significance is 2.78%. Taking 
into account all repeated 56 FNAs with confirmation of 
primary DC III diagnosis, the risk diminishes to 2.43%. 
Broome et al. showed higher risk of malignancy (9.2%) 
in this category [11], Chen et al. reported 19% [15], Ho 
et al. presented 38.6% after first FNA on a group of 
8862 patients [7].
The researchers praise the clarity of the Bethesda 
System and its simple transfer to clinical recommen-
dations, resulting in the limitation of the number of 
unnecessary surgical interventions. We cannot ignore 
major differences in the assessment of malignancy risk 
and considerable divergences in applying the recom-
mendations of the Bethesda System. Our definition of 
DC III without the group of atypical changes appears 
to be clearer and hence carries lower risk of malignancy 
and a smaller percentage of surgical interventions. 
Conclusions
In the analysed material, the risk of cancer in patients 
with FLUS is 2.78%. Taking into account all 56 sub-
sequent FNABs in which the primary diagnosis was 
confirmed, the risk decreases to 2.43%.
The diagnosis of FLUS in the absence of clinical 
indications is not a basis for surgical treatment.
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